Author: admin
 |
ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ — I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.
H.C. Wainwright 26th Annual Global Investment Conference
|
Presentation Time |
Tuesday, September 10 at 5:00 PM ET |
|
Presenters |
Sean Fu, PhD, Interim Chief Executive Officer (CEO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO) |
|
Webcast link |
|
|
Meetings |
One-on-one and small group meetings: September 9 – 10, 2024 |
|
Management |
Sean Fu, PhD, Interim CEO Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, CMO Tyler Ehler, Senior Director, Investor Relations |
The webcast will also be available under “Event Calendar” on I-Mab’s IR website
at https://ir.i-mabbiopharma.com/
For more information, please contact your H.C. Wainwright representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
Đề xuất
British Vlogger Stu: China’s Secret to Calmly Resolving Trade Disputes
US Federal Court Dismisses All Claims Against Binance in Anti – Terrorism Lawsuit
The 15th Five-Year Plan featuring opening up: China and the world sharing the future
Global Times: Deliver for real, and turn every policy into smiles on people’s faces
Visitors become entrepreneurs, discover opportunities in Yunnan
From Product Exports to Global Standards: Feng Xingya Outlines the Next Stage of China’s Auto Globalization